Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases.
Age-related macular degeneration
Diabetic retinopathy
Nanotherapy
RPE
Retinal diseases
Retinal pigment epithelium
Retinopathy of prematurity
Targeted drug delivery
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
10
01
2022
revised:
15
04
2022
accepted:
25
05
2022
pubmed:
3
6
2022
medline:
31
8
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
The retinal pigment epithelium (RPE) plays a crucial part in sight-threatening diseases. In this review, we shed light on the pivotal implication of the RPE in age-related macular degeneration, diabetic retinopathy and retinopathy of prematurity; and explain why a paradigm shift toward targeted RPE therapy is needed to efficiently fight these retinal diseases. We provide guidance for the development of RPE-specific nanotherapeutics by giving a comprehensive overview of the possibilities and challenges of drug delivery to the RPE and highlight successful nanotherapeutic approaches targeting the RPE.
Identifiants
pubmed: 35654389
pii: S1359-6446(22)00215-X
doi: 10.1016/j.drudis.2022.05.024
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2497-2509Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.